We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

76 hedge funds and large institutions have $239M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

280% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 10

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

23% more capital invested

Capital invested by funds: $195M → $239M (+$44.2M)

6% more funds holding

Funds holding: 72 → 76 (+4)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
76
Holders Change
+4
Holders Change %
+5.56%
% of All Funds
1.89%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
13
Increased
38
Reduced
10
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$14.6M
2
BlackRock
BlackRock
New York
+$5.17M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$4.58M
4
CC
Casdin Capital
New York
+$3.39M
5
FI
Fosun International
China
+$2.73M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.89M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$7.91M
3
DM
Deerfield Management
New York
-$3.48M
4
RG
Redmile Group
California
-$2.58M
5
Millennium Management
Millennium Management
New York
-$2.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$1.58M +$5.26K +372 +0.4%
BBA
27
Baker Bros. Advisors
New York
$1.56M – – –
Morgan Stanley
28
Morgan Stanley
New York
$1.49M +$1.18M +83,561 +676%
VIA
29
Vident Investment Advisory
Georgia
$1.1M +$30.3K +2,146 +3%
Millennium Management
30
Millennium Management
New York
$934K -$2.05M -144,793 -71%
OAM
31
Oxford Asset Management
United Kingdom
$927K +$89.5K +6,328 +12%
PCM
32
Parsons Capital Management
Rhode Island
$670K +$608K +43,016 New
TCIM
33
TIAA CREF Investment Management
New York
$657K -$316K -22,340 -35%
JP Morgan Chase
34
JP Morgan Chase
New York
$649K -$9.9K -700 -2%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$646K +$224K +15,848 +62%
Charles Schwab
36
Charles Schwab
California
$646K +$243K +17,218 +71%
SO
37
STRS Ohio
Ohio
$643K +$56.6K +4,000 +11%
American Century Companies
38
American Century Companies
Missouri
$532K +$27.3K +1,933 +6%
Russell Investments Group
39
Russell Investments Group
United Kingdom
$502K +$456K +32,224 New
AA
40
ALPS Advisors
Colorado
$494K +$37.4K +2,644 +9%
AIMCA
41
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$486K +$202K +14,300 +85%
First Manhattan
42
First Manhattan
New York
$482K +$438K +31,000 New
AIM
43
ARK Investment Management
Florida
$445K +$235K +16,600 +139%
California State Teachers Retirement System (CalSTRS)
44
California State Teachers Retirement System (CalSTRS)
California
$366K +$165K +11,700 +99%
Wells Fargo
45
Wells Fargo
California
$324K -$2.67K -189 -0.9%
Deutsche Bank
46
Deutsche Bank
Germany
$323K +$102K +7,233 +53%
NFA
47
Nationwide Fund Advisors
Ohio
$320K +$121K +8,577 +72%
VEA
48
Virtus ETF Advisers
New York
$316K +$26.2K +1,856 +10%
ARTA
49
A.R.T. Advisors
New York
$281K +$255K +18,064 New
TA
50
Teachers Advisors
New York
$250K +$67.9K +4,804 +43%
1
2
3 4

JNCE Hedge Fund Activity: Q3 2017 in Review

76 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q3 2017, worth a combined $239M — up 23% from $195M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new JNCE positions and 9 closed out — a net gain of 4 holders — while 38 added to existing stakes and 10 trimmed.

The largest buyer was PFM Health Sciences, adding an estimated $14.6M. The largest seller was Fidelity Investments, cutting an estimated $9.89M.

  • 76 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q3 2017, up from 72 in Q2 2017.
  • Funds reported $239M of Jounce Therapeutics, Inc. Common Stock stock for Q3 2017, up 23% quarter-over-quarter.
  • 13 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q3 2017 and 9 closed out, a net change of +4 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q3 2017 was PFM Health Sciences, an estimated $14.6M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q3 2017 was Fidelity Investments, an estimated $9.89M sold.

Based on aggregated 13F filings for Q3 2017.